Bayer's Balance-Sheet Overhaul and Q2 Beat Converge as Shares Close In on Analyst Targets
Published on 08/10/2026 at 02:40 | Redaktion boerse-global.de
The math behind Bayer's turnaround story is getting easier to follow. A €3 billion equity injection from Apollo Global Management, a heavily oversubscribed $5 billion bond sale, and a second-quarter earnings report that topped consensus expectations have combined to give the Leverkusen-based conglomerate its most credible recovery narrative in years.
Shares closed Friday at €49.90, up 1.05 percent on the day and 5.23 percent higher over the past week. Yet the stock still sits 7.35 percent below its 52-week high of €53.86, reached in early July — a gap that looks increasingly narrow given the momentum building across the company's operations and its capital structure.
Crop Science Carries the Quarter
The agricultural division delivered the standout performance in the three months through June. Operating profit at Crop Science jumped nearly a third to €902 million, propelled by efficiency programs and robust US demand for Dicamba seeds. Group-wide, currency- and portfolio-adjusted revenue rose 2.2 percent to €10.87 billion, while adjusted EBITDA gained 1.9 percent to €2.14 billion.
The bottom line swung decisively into positive territory. Net income reached €219 million in the second quarter, reversing a €199 million loss in the same period last year. That improvement prompted management to lift its full-year guidance for adjusted core earnings per share to a range of €4.20 to €4.70, up from the previous €4.10 to €4.60.
Deutsche Bank Research analyst Virginie Boucher-Ferte, who reiterated a "Buy" rating with a €60 price target on Friday, called the quarter solid and noted operating results came in 11 percent above consensus estimates.
Just as Bayer's turnaround hinges on disciplined risk management, so does your workplace's safety record. Many employers unknowingly leave gaps in their risk assessments — gaps that can prove costly in an inspection. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards properly and stay compliant. Download the free Risk Assessment Toolkit
A Two-Pronged Assault on Debt
The balance sheet is where the most consequential moves have taken place. On July 10, Bayer struck a deal with Apollo Global Management for a minority stake in a newly formed entity housing its long-acting reversible contraceptive (LARC) business. The transaction delivers €3.0 billion in equity to Bayer while leaving the company as majority owner with operational control. Closing is expected in the third quarter of 2026.
Just five days later, Bayer tapped the US capital markets through its Bayer US Finance LLC subsidiary, placing $5 billion in bonds across five tranches with maturities ranging from five to thirty years. The offering was multiple times oversubscribed, a signal that institutional investors remain comfortable with the company's creditworthiness despite ongoing litigation exposure. Closing occurred on July 20.
These moves have allowed management to sharpen its debt-reduction targets. The company now expects year-end 2026 net financial debt of €29 to €30 billion, down from a prior forecast of €32 to €33 billion. The adjustment comes even as the balance sheet shows the strain of the company's legal obligations: net financial debt stood at €33.647 billion on June 30, up 3.5 percent from the end of March, while second-quarter free cash flow came in at minus €371 million against plus €125 million a year earlier, weighed down by higher litigation-related payments.
Analyst Divergence Reflects the Debate
The investment community remains split on how much further the recovery can run. JPMorgan's Richard Vosser reaffirmed an "Overweight" rating with a €50.00 price target, anticipating modest upward revisions to full-year earnings estimates following the quarterly results. Jefferies, by contrast, held firm at "Hold" with a €46.00 target, though the firm explicitly praised the better-than-expected revenue performance.
Notably, the current share price already sits above the Jefferies target and within striking distance of JPMorgan's — a sign that the recent rally has outpaced at least part of the sell-side's expectations.
Legal Calendar Slips, But the Trend Is Favorable
The courtroom calendar continues to shift in ways that, while procedural, reinforce the sense of easing pressure. A Missouri court has pushed back the hearing for final approval of the $7.25 billion glyphosate class-action settlement from August 19 to September 14, 2026, to process withdrawal requests following the US Supreme Court's June 25 ruling in the Durnell case. The 7-2 decision favored Bayer, establishing that the federal FIFRA statute preempts state-level failure-to-warn claims when the EPA has approved product labels.
CEO Bill Anderson has struck a confident tone on the legal front, describing the company's position as strong with key milestones ahead in its containment strategy.
The convergence of operational stabilization, a shrinking debt burden, and a more favorable legal landscape has nearly doubled the stock over the past twelve months from its trough. Whether the shares can reclaim their July peak will likely depend on how smoothly the remaining legal proceedings unfold — and whether the company can keep delivering the kind of numbers that have analysts reaching for their calculators.
